Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
n-acetyl-aspartyl-glutamate
- Development stage
- Phase 4
- Lead developer
- Théa Pharmaceuticals
- Modality
- Small Molecules, Peptides
- Administration
- Ophthalmic
01
Overview
N-acetyl-aspartyl-glutamate (NAAGA), also known as spaglumic acid, is a peptide-based small molecule mast cell stabilizer developed by Laboratoires Théa. It is primarily used for the treatment of allergic eye conditions, including vernal keratoconjunctivitis (VKC) and allergic conjunctivitis. NAAGA exerts its therapeutic effects through multiple anti-inflammatory pathways: it inhibits mast cell degranulation, modulates complement activation, reduces the production of inflammatory mediators like leukotrienes, and decreases the expression of eosinophil surface-adhesion molecules. The formulation "Naaxia Sine" is a preservative-free ophthalmic solution delivered via the ABAK multidose system to minimize ocular surface irritation and is often compared to other antihistamines or mast cell stabilizers in clinical settings.
- Brand names
- Naaxia SineNaaxia
- Other names
- NAAGAspaglumic acidN-acetyl-aspartyl-glutamic acidmagnesium spaglumatesodium spaglumate
02
Targets
GRM3 (mGluR3)Complement (Complement system)CysLTR (Cysteinyl leukotriene receptor family)
Beyond the preview
Go deeper on n-acetyl-aspartyl-glutamate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on n-acetyl-aspartyl-glutamate.